We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sweat Chloride Quantified Using Capillary Electrophoresis

By LabMedica International staff writers
Posted on 18 Feb 2019
Print article
Image: The Wyn-CE Adaptive Capillary Electrophoresis system and ER815 C4D Detector (Photo courtesy of WynSep).
Image: The Wyn-CE Adaptive Capillary Electrophoresis system and ER815 C4D Detector (Photo courtesy of WynSep).
Cystic fibrosis (CF) is the less rare and severe genetic disease among the European population. Biochemical diagnosis of CF is based on the demonstration of increased chloride concentration in sweat samples, obtained during the sweat test (ST).

Capillary electrophoresis (CE) is able to directly measure chloride. CE is already known as a high performance separation technique, quick and a low-sample volume consumer/user, for and with different matrixes. This method has been shown as a useful tool for analysis of sweat chloride.

Scientists at the Hôpital Purpan (Toulouse, France) and their colleagues carried out a study on subjects referred to our laboratory for a ST between May and August 2017. During this period, a total of 65 sweat samples were processed for the diagnosis or for the initiation or follow-up of a new treatment. The mean age of all 48 subjects was 9.8 ± 10.7 years; median 5 (ranging from 0.1 to 58) years. The sweat induction was carried out by pilocarpine iontophoresis, the gold standard, with Webster Sweat Inducer. Then sweat was collected during 25 minutes with Macroduct collector.

The team used the ELITech Wescor ChloroChek Chloridometer test system, model 3400, to measure the chloride in human sweat using the principle of coulometric titration. This assay required at least 10 µL of sweat and provided a digital readout in mmol/L. A comparison test was performed with a capillary electrophoresis with contactless conductivity detection system (CE-C4D). This assay required only 2 µL.

The investigators reported that the concentration of sweat chloride, determined by coulometry, allowed them to distinguish three groups of patients, according to the new consensus guideline: (i) control group of 44 with chloride less than 30 mmol/L; three subjects as borderline group with chloride between 30 and 59 mmol/L; and a CF group of 18 with chloride equal to or greater than 60 mmol/L. The method validation showed comparable analytical performances for both methods; no false positive or false negative was recorded. The two methods showed a high correlation and a close agreement was demonstrated by two different statistical tests.

The authors concluded that WynSep CE is an accurate, fast, easy-to-use method and an appropriate technique for CF diagnosis. The WynSep CE device also offers a strong financial advantage, and as it is not dedicated to only sweat chloride assay and can be used for measurement of a variety of analytes. The study was published in the January 2019 issue of the journal Practical Laboratory Medicine.

Related Links:
Hôpital Purpan


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.